Pulmatrix Inc PULM

NAS: PULM | ISIN: US74584P2020   20:54
1,935 USD (+4,03%)
(+4,03%)   20:54

28 maart 2024 · Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update · Persbericht

8 januari 2024 · Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives · Persbericht

9 november 2023 · Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

19 september 2023 · Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine · Persbericht

23 augustus 2023 · Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole · Persbericht

10 augustus 2023 · Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

11 juli 2023 · Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine · Persbericht

15 juni 2023 · Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society · Persbericht

24 mei 2023 · Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention · Persbericht

12 mei 2023 · Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

2 mei 2023 · Pulmatrix Supports World Asthma Day 2023 · Persbericht

30 maart 2023 · Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update · Persbericht

6 februari 2023 · Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma · Persbericht

25 januari 2023 · Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" · Persbericht

23 januari 2023 · Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology · Persbericht

4 januari 2023 · Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine · Persbericht

10 november 2022 · Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

26 september 2022 · Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine · Persbericht

8 augustus 2022 · Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

12 juli 2022 · Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine · Persbericht

Mijn selecties